Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women aged 18-65 years old~2. Patients applying to one of the followings 2.1. BMI 30kg/m2 or over 2.2. BMI 27-29.9kg/m2 with hypertension in a proper treatment and blood pressure controlled (SBP ≤ 145mmHg, DBP ≤ 95mmHg) 2.3. BMI 27-29.9kg/m2 with non-insulin-dependent diabetes mellitus and fasting blood glucose \< 7.8mmol/L(140mg/dL) 2.4. BMI 27-29.9kg/m2 with hyperlipidemia in a proper treatment 2.5. BMI 27-39.9kg/m2 and Total cholesterol 236mg/dL or over or Triglyceride 150mg/dL or over at screening~3. Agreed to low-calorie diet during the trial~4. Written informed consent of the trial~Exclusion Criteria:~1. Endocrine disease such as hypothyroidism, Cushing's syndrome, etc.~2. Heart disease (heart failure, angina pectoris, myocardial infarction)~3. Uncontrolled hypertension (SBP \> 145 mmHg or DBP \> 95 mmHg)~4. Malignant tumour or lung disease~5. Cholelithiasis~6. Severe renal disability (SCr \> 2.0 mg/dL)~7. Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\], alkaline phosphatase)~8. Non-insulin-dependent diabetes mellitus and fasting blood sugar 7.8mmol/L (140 mg/dL) or over~9. Narrow angle glaucoma~10. History or existence of neurological or psychological disease (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.)~11. History of stroke or temporary ischemic cardioplegia~12. History or existence of eating disorder such as anorexia nervosa or bulimia nervosa, etc.~13. Use of medication that could have effect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medication having effect on absorption, metabolism, excretion)~14. Use of β--blocker or diuretic as hypertension medication within last 3 months~15. Use of medication for central nervous system or central active weight reduction medication~16. Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)~17. Difficult to measure anthropometric dimensions because of anatomical change such as resection~18. Surgical history for weight reduction; bariatric surgery, etc.~19. Unable to follow instructions of the trial as judged by investigator~20. Women who were pregnant, lactating, planning a pregnancy or women of childbearing age who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.) (Women of childbearing age indicate within 2 years of menopause who did not receive hysterectomy, bilateral tubal ligation, bilateral oophorectomy, etc.)~21. Use of other investigational product within last 1 month~22. Reduction over 10% of the previous weight within 6 months~23. Decided to stop smoking within last 3 months; however, keeping irregular smoking habit

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Euiiyin-tang (Type: EXPERIMENTAL): powder type, 3 times per day before the meal, 12 weeks total
- Placebo (Type: PLACEBO_COMPARATOR): powder type, 3 times per day before the meal, 12 weeks total

Based on this trial design, predict the completion outcome and termination type (if applicable).